JP2013516469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516469A5 JP2013516469A5 JP2012548078A JP2012548078A JP2013516469A5 JP 2013516469 A5 JP2013516469 A5 JP 2013516469A5 JP 2012548078 A JP2012548078 A JP 2012548078A JP 2012548078 A JP2012548078 A JP 2012548078A JP 2013516469 A5 JP2013516469 A5 JP 2013516469A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- human
- antigen
- immune response
- stimulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 7
- 102000038129 antigens Human genes 0.000 claims 7
- 108091007172 antigens Proteins 0.000 claims 7
- 230000028993 immune response Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000004936 stimulating Effects 0.000 claims 4
- 108010040721 Flagellin Proteins 0.000 claims 3
- 208000006572 Human Influenza Diseases 0.000 claims 3
- 206010022000 Influenza Diseases 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 3
- 102000004965 antibodies Human genes 0.000 claims 3
- 102000037240 fusion proteins Human genes 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 108010061543 Neutralizing Antibodies Proteins 0.000 claims 1
- 101710043164 Segment-4 Proteins 0.000 claims 1
- 101700038759 VP1 Proteins 0.000 claims 1
- 238000006065 biodegradation reaction Methods 0.000 claims 1
- 101700005460 hemA Proteins 0.000 claims 1
- 239000000185 hemagglutinin Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
Claims (11)
- 少なくとも１種類のフラジェリンの少なくとも一部と、少なくとも１種類の抗原の少なくとも一部とを含む融合タンパク質を含む医薬組成物であって、該組成物は約０．５μｇを超える用量で前記人間に投与され、前記人間は少なくとも４９才である、人間における免疫応答を刺激するための医薬組成物。
- 前記人間は４９才と約６４才との間の年齢である、請求項１に記載の組成物。
- 前記人間は少なくとも６５才の年齢である、請求項１に記載の組成物。
- 前記用量は、０．５μｇ、１μｇ、２μｇ、３μｇ、４μｇ、５μｇ、６μｇ、７μｇ、８μｇ、１０μｇ、１５μｇ、２０μｇ、２５μｇ及び３０μｇからなる群より選択される少なくとも１種類の用量である、請求項１に記載の組成物。
- 前記抗原はインフルエンザ抗原である、請求項１に記載の組成物。
- 前記インフルエンザ抗原はヘマグルチニンインフルエンザ抗原である、請求項５に記載の組成物。
- 前記融合タンパク質は配列番号１を含む、請求項１に記載の組成物。
- 少なくとも１種類のフラジェリンの少なくとも一部と、少なくとも１種類の抗原の少なくとも一部とを含む融合タンパク質を含む、高齢者集団における免疫応答を刺激するための医薬組成物であって、抗体応答率が少なくとも７５％であり、前記組成物が投与される高齢者集団の人間は少なくとも４９才である、組成物。
- 少なくとも１種類のフラジェリンの少なくとも一部と、粒子と会合する、少なくとも１種類の抗原の少なくとも一部とを含む、人間における免疫応答を刺激するための医薬組成物であって、前記組成物が投与される前記人間は少なくとも４９才である、組成物。
- 前記粒子は、ビロソーム、リポソーム、生分解性マイクロスフィア、自己集合性ペプチドナノ粒子、ウイルス様粒子又はこれらの組合せである、請求項９に記載の組成物。
- 高齢者集団における免疫応答を刺激するための医薬組成物であって、少なくとも３μｇの配列番号１を含み、前記組成物の前記高齢者集団への投与によって生じる免疫応答は、
抗体陽転率が、５０％を超えるか、６０％を超えるか、７０％を超えるか、８０％を超えるか、９０％を超えるか、９５％を超えるか、９９％を超えるかであること、
抗体保持率が、５０％を超えるか、６０％を超えるか、７０％を超えるか、８０％を超えるか、９０％を超えるか、９５％を超えるか、９９％を超えるかであること、又は、
ワクチン接種後の中和抗体力価が平均４倍以上上昇することの基準のうち１つに該当するか、あるいは、超える、組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29259310P | 2010-01-06 | 2010-01-06 | |
| US61/292,593 | 2010-01-06 | ||
| PCT/US2011/020159 WO2011084967A2 (en) | 2010-01-06 | 2011-01-05 | Methods and compositions for providing protective immunity in the elderly |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013516469A JP2013516469A (ja) | 2013-05-13 |
| JP2013516469A5 true JP2013516469A5 (ja) | 2014-02-20 |
Family
ID=44306116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548078A Pending JP2013516469A (ja) | 2010-01-06 | 2011-01-05 | 高齢者に保護免疫を提供するための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130095130A1 (ja) |
| EP (1) | EP2521563B1 (ja) |
| JP (1) | JP2013516469A (ja) |
| KR (1) | KR20120129893A (ja) |
| CN (1) | CN102740872A (ja) |
| AU (1) | AU2011203740B2 (ja) |
| CA (1) | CA2786306A1 (ja) |
| MX (1) | MX2012007916A (ja) |
| SG (1) | SG182305A1 (ja) |
| WO (1) | WO2011084967A2 (ja) |
| ZA (1) | ZA201205273B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG158894A1 (en) | 2005-01-19 | 2010-02-26 | Vaxinnate Corp | Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response |
| TW200745158A (en) | 2006-03-07 | 2007-12-16 | Vaxinnate Corp | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| EP3115060A1 (en) | 2008-04-18 | 2017-01-11 | VaxInnate Corporation | Deletion mutants of flagellin and methods of use |
| US8932598B2 (en) * | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976552A (en) * | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
| US20030232055A1 (en) * | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
| US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
| EP1824510B1 (en) * | 2004-12-16 | 2012-10-31 | Wake Forest University Health Sciences | Use of flagellin in the immunotherapy of yersinia pestis |
| JP2008524261A (ja) * | 2004-12-21 | 2008-07-10 | バクシネート コーポレーション | インフルエンザウイルスタンパク質の組成物およびその使用方法 |
| US20090162400A1 (en) * | 2004-12-21 | 2009-06-25 | Powell Thomas J | Compositions of influenza viral proteins and methods of use thereof |
| WO2006083792A2 (en) * | 2005-01-31 | 2006-08-10 | Vaxinnate Corporation | Novel polypeptide ligands for toll-like receptor 2 (tlr2) |
| PE20061428A1 (es) * | 2005-03-23 | 2007-01-16 | Glaxosmithkline Biolog Sa | Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl |
| TW200745158A (en) * | 2006-03-07 | 2007-12-16 | Vaxinnate Corp | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| EP3115060A1 (en) * | 2008-04-18 | 2017-01-11 | VaxInnate Corporation | Deletion mutants of flagellin and methods of use |
| BRPI0911604A2 (pt) * | 2008-04-25 | 2015-12-15 | Inst Systems Biology | vacinas de polipeptídeo de flagelina |
-
2011
- 2011-01-05 WO PCT/US2011/020159 patent/WO2011084967A2/en active Application Filing
- 2011-01-05 SG SG2012048617A patent/SG182305A1/en unknown
- 2011-01-05 CA CA2786306A patent/CA2786306A1/en not_active Abandoned
- 2011-01-05 JP JP2012548078A patent/JP2013516469A/ja active Pending
- 2011-01-05 MX MX2012007916A patent/MX2012007916A/es not_active Application Discontinuation
- 2011-01-05 EP EP11732058.0A patent/EP2521563B1/en not_active Not-in-force
- 2011-01-05 AU AU2011203740A patent/AU2011203740B2/en not_active Ceased
- 2011-01-05 CN CN2011800069618A patent/CN102740872A/zh active Pending
- 2011-01-05 KR KR1020127019714A patent/KR20120129893A/ko not_active Application Discontinuation
- 2011-01-05 US US13/519,912 patent/US20130095130A1/en not_active Abandoned
-
2012
- 2012-07-16 ZA ZA2012/05273A patent/ZA201205273B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Al-Halifa et al. | Nanoparticle-based vaccines against respiratory viruses | |
| Zaman et al. | Strategies for intranasal delivery of vaccines | |
| Sulczewski et al. | Nanoparticle vaccines against viral infections | |
| Tao et al. | M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection | |
| Dhakal et al. | Polyanhydride nanovaccine against swine influenza virus in pigs | |
| HRP20171213T1 (hr) | Glikoproteinske čestice nalik virusu (vlp) bjesnoće | |
| JP2017538672A5 (ja) | ||
| JP2011250797A5 (ja) | ||
| Wang et al. | Double‐Layered M2e‐NA Protein Nanoparticle Immunization Induces Broad Cross‐Protection against Different Influenza Viruses in Mice | |
| JP2013530158A5 (ja) | ||
| Dehghan et al. | Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants | |
| TW201427724A (zh) | 經鼻流感疫苗組成物 | |
| Ibanez et al. | M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A | |
| Watkins et al. | A single dose and long lasting vaccine against pandemic influenza through the controlled release of a heterospecies tandem M2 sequence embedded within detoxified bacterial outer membrane vesicles | |
| RU2017137357A (ru) | Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал | |
| JP2013518052A5 (ja) | ||
| Renukaradhya et al. | Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation | |
| JP2010506926A5 (ja) | ||
| JP2013516469A5 (ja) | ||
| Chan et al. | Advanced drug delivery systems can assist in managing influenza virus infection: A hypothesis | |
| JPWO2015152360A1 (ja) | 不活化全粒子ワクチンを含有するマイクロニードルアレイ製剤およびその投与方法 | |
| BR112019013724A2 (pt) | composições de vacina influenza universal | |
| Wang et al. | The potential adjuvanticity of quaternized chitosan hydrogel based microparticles for porcine reproductive and respiratory syndrome virus inactivated vaccine | |
| Cossette et al. | Intranasal subunit vaccination strategies employing nanomaterials and biomaterials | |
| Jampílek et al. | Nanoformulations: a valuable tool in the therapy of viral diseases attacking humans and animals |